Speeding up the Evaluation of New Agents in Cancer

Affiliations of authors: MRC Clinical Trials Unit, London, UK (MKBP, MS, RL, RK, AMS, WQ, PR); Institute of Psychiatry, King’s College London, London, UK (FMSB); NCIC Clinical Trials Group, Queen's University, Kingston, Ontario, Canada (EE); School of Public Health and Health Professions, University at Buffalo, Buffalo, NY (MB); CR-UK Institute for Cancer Studies, University of Birmingham, Birmingham, UK (NJ); Fox Chase Cancer Center, Philadelphia, PA (MAB)
CancerSpectrum Knowledge Environment (Impact Factor: 15.16). 10/2008; 100(17):1204-14. DOI: 10.1093/jnci/djn267
Source: PubMed

ABSTRACT Despite both the increase in basic biologic knowledge and the fact that many new agents have reached various stages of development during the last 10 years, the number of new treatments that have been approved for patients has not increased as expected. We propose the multi-arm, multi-stage trial design as a way to evaluate treatments faster and more efficiently than current standard trial designs. By using intermediate outcomes and testing a number of new agents (and combinations) simultaneously, the new design requires fewer patients. Three trials using this methodology are presented.

Download full-text


Available from: Matthew R Sydes, Aug 19, 2015
  • [Show abstract] [Hide abstract]
    ABSTRACT: Despite the gains that had been made in increasing overall survival and extending disease-free survival rates, cancer is still one of the leading causes of death in the United States [1]. There remains an urgent need for the rapid development of new cancer therapeutics. Unfortunately, only about 5% of new compounds intended for use in cancer therapy are approved for clinical use [2]. The time and enormous costs involved in conducting clinical trials are special barriers to drug development [3, 4]. Careful thought regarding each phase of investigation is critical for the successful and efficient completion and interpretation of a clinical trial and prior to widespread clinical use of a new drug. This chapter focuses on clinical trials in oncology and translational applications. The global objectives of cancer clinical trials are to evaluate promising, new agents that may alleviate symptoms and/or cure the disease. As newer agents such as molecular targeted therapies are developed, questions remain as to whether current models of clinical trial design are sufficient. Nevertheless, classic design forms the basis of drug development in cancer therapy. Study objectives and endpoints are associated with specific study designs and determine the level of testing and the number of subjects required for each phase (Fig. 1) [5].
  • [Show abstract] [Hide abstract]
    ABSTRACT: In this paper, we investigate some properties of identification matrices and exhibit some uses of identification matrices in studying the graph isomorphism problem, a well-known long-standing open problem. We show that, given two m×n identification matrices representing two graphs according to a certain relation, isomorphism can be decided efficiently in parallel if an m×(n-c) submatrix, for a constant c, satisfies the consecutive/circular 1's property. The result presented here significantly broadens the class of graphs for which there are known efficient parallel isomorphism testing algorithms
    Parallel Architectures, Algorithms and Networks, 1994. (ISPAN), International Symposium on; 01/1995
  • [Show abstract] [Hide abstract]
    ABSTRACT: The paper treats mapping (interpolation) of the output vector from an existing antenna array onto the output vector of an imaginary array when the directions of arrival (DOA) are known only to within a sector. The problem of constructing a mapping matrix, common to the sector, that minimizes DOA mean square error (MSE) across the sector, is analyzed. We derive a general condition on the mapping errors that prevents them from affecting the calculated DOAs. Thereafter, we propose a design algorithm for the transformation matrix that generates mapping errors fulfilling this condition. Simulations show conspicuous MSE improvements in relevant scenarios.
    Signals, Systems and Computers, 2002. Conference Record of the Thirty-Sixth Asilomar Conference on; 12/2002
Show more